Scarica l'app Stockscreener
60.61
0.05%
0.03
Dopo l'orario di chiusura:
60.60
-0.010
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$60.58
Aprire:
$60.41
Volume 24 ore:
224.40K
Relative Volume:
0.60
Capitalizzazione di mercato:
$2.10B
Reddito:
-
Utile/perdita netta:
$-91.00M
Rapporto P/E:
-16.51
EPS:
-3.67
Flusso di cassa netto:
$-74.38M
1 W Prestazione:
+4.92%
1M Prestazione:
+12.42%
6M Prestazione:
+5.50%
1 anno Prestazione:
+38.00%
Intervallo 1D:
$59.47
$60.83
Intervallo di 1 settimana:
$57.42
$61.73
Portata 52W:
$30.82
$68.73
Disc Medicine Inc Stock (IRON) Company Profile
Nome
Disc Medicine Inc
Settore
Industria
Telefono
(617) 674-9274
Indirizzo
321 ARSENAL STREET, SUITE 101, WATERTOWN
Confronta IRON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
60.61 | 2.10B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-11 | Ripresa | Raymond James | Strong Buy |
| 2025-02-27 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-01 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-17 | Iniziato | Raymond James | Outperform |
| 2023-04-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Iniziato | Stifel | Buy |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2023-03-23 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Disc Medicine Inc Borsa (IRON) Ultime notizie
Insider Selling at Disc Medicine Inc.: A Balancing Act Between Portfolio Strategy and Investor Sentiment - AInvest
Is Disc Medicine Inc. a good long term investmentFree Stock Movement Tracking - PrintWeekIndia
Can Disc Medicine Inc. stock recover from recent declineSuperior profit margins - jammulinksnews.com
What drives Disc Medicine Inc. stock priceBreakthrough capital growth - PrintWeekIndia
10 Best Mid Cap Stocks to Buy According to Billionaires - Insider Monkey
Is Disc Medicine Inc. stock overhyped or has real potentialBreakthrough wealth creation - jammulinksnews.com
Disc Medicine Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - Autocar Professional
What analysts say about Disc Medicine Inc. stockUnrivaled growth potential - Autocar Professional
Disc Medicine’s Strategic Advancements and Regulatory Progress Drive Buy Rating - TipRanks
Disc Medicine To Seek FDA Approval For Bitopertin In EPP, A Painful Sunlight Sensitivity Disorder - Nasdaq
Disc Medicine’s (IRON) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Disc Medicine's NDA Submission for Bitopertin in EPP: A Catalyst-Driven Opportunity in a High-Unmet-Need Market - AInvest
Disc Medicine to submit NDA for bitopertin in EPP in October By Investing.com - Investing.com India
Truist Securities initiates Disc Medicine stock with Buy rating, $86 target - Investing.com Canada
Disc Medicine to submit NDA for bitopertin in EPP in October - Investing.com Australia
Disc Medicine, Inc. Receives Positive FDA Feedback for Bitopertin NDA Submission in Erythropoietic Protoporphyria - Nasdaq
Disc Medicine Announces Positive Pre-NDA Meeting and - GlobeNewswire
why disc medicine inc. stock attracts strong analyst attentionReal Time Stock Signal - Newser
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85 - 富途牛牛
Disc Medicine(IRON) Soars 7.28% on Insider Trading, Analyst Rating - AInvest
Disc medicine CFO Franchi sells $119k in shares - Investing.com
Disc medicine CFO Franchi sells $119k in shares By Investing.com - Investing.com India
Raymond James reiterates Strong Buy on Disc Medicine stock amid Bristol Myers trial results - Investing.com Canada
Why Disc Medicine Inc. stock attracts strong analyst attentionMarket Ready Callouts - Newser
How Disc Medicine Inc. stock performs during market volatilityCapital Safe Stock Watchlist - Newser
What makes Disc Medicine Inc. stock price move sharplyRisk Adjusted Stock Signals - Newser
Disc Medicine Elects Nadim Ahmed as Director - The Globe and Mail
Disc Medicine Inc Azioni (IRON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):